Antibody for resisting novel coronavirus, preparation method and application
阅读说明：本技术 抗新型冠状病毒的抗体、制备方法和应用 (Antibody for resisting novel coronavirus, preparation method and application ) 是由 张黎 朱凤才 郑滨洋 高行素 郭喜玲 陈银 王祥喜 潘红星 孟繁岳 朱玲 孙瑶 于 2020-05-28 设计创作，主要内容包括：本发明公开了抗新型冠状病毒的抗体、制备方法和应用。本发明还涉及编码抗体的核酸分子。本发明还涉及使用这些抗体进行诊断和治疗的方法。(The invention discloses an antibody for resisting novel coronavirus, a preparation method and application. The invention also relates to nucleic acid molecules encoding the antibodies. The invention also relates to diagnostic and therapeutic methods using these antibodies.)
1. An antibody or antigen-binding fragment thereof that specifically binds to a novel coronavirus S protein, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the CDR regions of the sequences set forth in SEQ ID nos. 1-3.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID No. 4.
3. The antibody or antigen-binding fragment thereof of claim 1, further comprising a light chain variable region comprising the CDR regions of the sequences set forth in SEQ ID nos. 5-7.
4. The antibody or antigen-binding fragment thereof of claim 3, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID No. 8.
5. A polynucleotide molecule encoding the antibody or antigen-binding fragment thereof of any one of claims 1-4; preferably, the polynucleotide molecule comprises the sequences shown in SEQ ID No.9 and 10.
6. An expression vector comprising the polynucleotide molecule of claim 5 and an expression control sequence operably linked thereto.
7. A host cell transformed with the polynucleotide molecule of claim 5 or the expression vector of claim 6.
8. A method of making an antibody or antigen-binding portion thereof that specifically binds to a novel coronavirus S protein, said method comprising the step of culturing the host cell of claim 7.
9. A composition or kit comprising the antibody or antigen-binding fragment thereof of any one of claims 1-4.
10. A use comprising the use of any one of:
(1) use of the antibody or antigen-binding fragment thereof of any one of claims 1-4 for the preparation of a novel coronavirus detection product or diagnostic product;
(2) use of the antibody or antigen-binding fragment thereof of any one of claims 1-4 in the manufacture of a medicament for the prevention or treatment of a novel coronavirus infection;
(3) use of the antibody or antigen-binding fragment thereof of any one of claims 1-4 in the manufacture of a medicament for the prevention or treatment of a disease caused by a novel coronavirus infection;
(4) use of a composition according to claim 9 for the preparation of a novel coronavirus detection product or diagnostic product;
(5) use of a composition according to claim 9 for the preparation of a medicament for the prevention or treatment of a novel coronavirus infection;
(6) use of the composition of claim 9 for the preparation of a medicament for the prevention or treatment of diseases infected by a novel coronavirus.
Technical Field
The invention belongs to the fields of cellular immunology and molecular biology, and relates to an antibody for resisting a novel coronavirus, a preparation method and application.
Background
The international committee for viral classification named the novel coronavirus SARS-CoV-2 and the world health organization named the pneumonia caused by infection with this virus COVID-19. The virus has strong infectivity and wide transmission path. The virus can adapt to the environment of human body rapidly, has transmission capability in latent period after infection, and reports by some asymptomatic infectors that virus nucleic acid is detected even in various animals. These factors complicate the control of the virus and no effective therapeutic drugs and vaccines are currently on the market.
SARS-CoV-2 belongs to the genus Coronavirus, is a single-stranded positive-strand RNA virus, has a size of about 30kb, has a similarity of 79% to SARS-CoV, and has a similarity of up to about 88% to a Coronavirus (CoV) isolated from Bats. SARS-CoV-2 has typical coronavirus characteristics, and the virus envelope has typical spinous processes, which are shaped like coronages. The Spike protein (Spike protein) is the most important surface membrane protein of coronavirus, determines the host range and specificity of virus, and is an important site of host neutralizing antibody and a key target point of vaccine design.
Because specific therapeutic drugs and effective vaccines have not been developed successfully, attempts to treat critically ill patients with convalescent patient plasma have been made and have been shown to have significant efficacy. Due to the complex composition of plasma and plasma products, and the potential risk factors. Neutralizing antibodies to viruses, particularly fully human monoclonal antibodies, are of particular importance in viral diagnosis and therapy. The monoclonal antibody can recognize single epitope of virus, and some monoclonal antibodies with neutralization can infect adhesion host cells in the life cycle of the virus by binding to specific sites of the virus, such as receptor binding sites, protease cleavage sites and attachments of membrane fusion sites, and can play a role in neutralization by utilizing mechanisms of membrane fusion, surface proteolysis and the like. Wherein the fully human monoclonal antibody obtained from convalescent patients has more potential for drug development. Firstly, because the immune system in the convalescent patient is subjected to sufficient immune response, B cells are subjected to sufficient somatic high-frequency mutation, and the affinity of the antibody is matured to the maximum extent. And secondly, because the human immune system fully-humanized antibody does not generate immune response, the humanized antibody patent medicine is safer. Therefore, the human antibody with high affinity and high neutralizing activity has great application value in the aspects of controlling the novel coronavirus epidemic situation and treating severe patients.
Disclosure of Invention
The present invention provides antibodies or antigen-binding fragments thereof that specifically bind to a novel coronavirus S protein. These antibodies are human monoclonal antibodies.
According to one aspect of the present invention, there is provided an antibody or antigen-binding fragment thereof capable of specifically binding to a novel coronavirus S protein, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising CDR regions of the sequences set forth in SEQ ID nos. 1-3.
In a specific embodiment of the invention, the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO. 4.
The antibody or antigen-binding fragment thereof of the present invention further comprises a light chain variable region comprising the CDR regions of the sequences set forth in SEQ ID Nos. 5-7.
In a specific embodiment of the invention, the light chain variable region comprises the amino acid sequence shown in SEQ ID NO. 8.
The antibody or antigen-binding fragment thereof of the invention may be an immunoglobulin g (IgG), IgM, IgE, IgA or IgD molecule, and in a preferred embodiment, the human antibody is an IgG. May be of the IgG1, IgG2, IgG3, or IgG4 subtype. Such antibodies or antigen-binding fragments thereof may be derived from Fab fragments, F (ab') 2 fragments, Fv fragments, single chain antibodies or chimeric antibodies.
In some embodiments, the antibodies of the invention or antigen binding fragments thereof may be part of a fusion protein.
According to another aspect of the invention there is provided a polynucleotide molecule comprising the coding sequence of the antibody or antigen-binding fragment thereof as hereinbefore described, in particular nucleotide sequences encoding the heavy and light chain variable regions, the contiguous amino acid sequences encoding the heavy and
The nucleic acid molecule comprises the sequences shown in SEQ ID NO.9 and 10.
According to a further aspect of the invention, there is provided an expression vector comprising a polynucleotide molecule as hereinbefore described.
Further, the expression vector further comprises an expression control sequence operably linked to the polynucleotide molecule as described above.
According to a further aspect of the invention there is provided a host cell transformed with a polynucleotide molecule as hereinbefore described or an expression vector as hereinbefore described.
According to a further aspect of the invention, there is provided a composition which may be a labelled or derivatised antibody or antigen binding fragment thereof as hereinbefore described. In one embodiment, such an antibody or antigen-binding fragment thereof is labeled with a radioactive label, an enzymatic label, a toxin, a magnetic substance, or a drug conjugate. In another embodiment, such an antibody or antigen-binding fragment thereof is derivatized to improve one or more properties thereof, such as half-life, bioavailability, or activity. In a preferred embodiment, such an antibody or antigen-binding fragment thereof is derivatized with polyethylene glycol, at least 1 methyl or ethyl group or at least one sugar chain. In another preferred embodiment, the labeled or derivatized antibody or antigen-binding fragment thereof is used in a diagnostic or therapeutic method.
The composition may be a pharmaceutical composition comprising the antibody and one or more carriers, excipients and/or diluents. The pharmaceutical compositions may be formulated for specific uses, for example for veterinary use or for human pharmaceutical use.
For therapeutic use, the pharmaceutical composition may be provided as part of a sterile, pharmaceutical composition that includes a pharmaceutically acceptable carrier. Such a composition may be in any suitable form, depending on the desired method of administering it to a subject (i.e., patient), such as a human subject. The pharmaceutical composition can be administered to a subject using a variety of routes, such as oral, transdermal, subcutaneous, intranasal, intravenous, intramuscular, intratumoral, intrathecal, topical or topical. The most suitable route of administration in any given case will depend on the particular antibody, the subject, and the nature and severity of the disease and the physiological condition of the subject. Typically, the pharmaceutical composition should be administered intravenously or subcutaneously.
The pharmaceutical composition may be conveniently presented in unit dosage form containing a predetermined amount of an antibody described herein per dose. The amount of antibody included in a unit dose will depend on the disease being treated and other factors as is well known in the art. Such unit doses may be in the form of a lyophilized powder containing an amount of antibody suitable for a single administration, or in the form of a liquid. The dry powder unit dosage form may be packaged in a kit with a syringe, an appropriate amount of diluent, and/or other components useful for administration. The unit dose in liquid form may suitably be provided in the form of a syringe prefilled with an amount of antibody suitable for a single administration.
The pharmaceutical composition may also be provided in the form of a block containing an amount of antibody suitable for multiple administrations.
Pharmaceutical compositions for storage as lyophilized formulations or aqueous solutions can be prepared by mixing an antibody of the desired purity with optionally selected pharmaceutically acceptable carriers, excipients, or stabilizers (all referred to herein as "carriers"), i.e., buffers, stabilizers, preservatives, ionic isotonicity agents, nonionic detergents, antioxidants, and other miscellaneous additives commonly employed in the art. See Remington's Pharmaceutical Sciences [ Remington's Pharmaceutical Sciences ], 16 th edition (Osol edition, 1980). Such additives should be non-toxic to the recipient at the dosages and concentrations employed.
Buffering agents help to maintain the pH in a range near physiological conditions. It can be present in a wide variety of concentrations, but should generally be present in a concentration ranging from about 2mM to about 50 mM. Buffers suitable for use with the present disclosure include both organic and inorganic acids and salts thereof, such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, trisodium citrate mixture, monosodium citrate-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g., gluconic acid-sodium gluconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium gluconate mixture, etc.), oxalate buffers (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc.), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-potassium hydroxide mixture, lactic acid-potassium lactate mixture, etc.), and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, etc.). In addition, fumarate buffers, histidine buffers, and trimethylamine salts, such as 2-amino-2-hydroxymethyl-propane-1, 3-diol (i.e., Tris, THAM, or Tris (hydroxymethyl) aminomethane) can be used.
Isotonic agents, sometimes referred to as "stabilizers," may be added to ensure isotonicity of the liquid compositions of the present invention and include polyhydric sugar alcohols, e.g., trihydric or higher sugar alcohols, such as glycerol, erythritol, arabitol, xylitol, sorbitol, and mannitol. Stabilizers refer to a wide variety of excipients that range in function from bulking agents to additives that dissolve the therapeutic agent or help prevent denaturation or adhesion to the container walls. Typical stabilizers may be polyhydric sugar alcohols (listed above); amino acids (e.g., arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc.), organic sugars or sugar alcohols (e.g., lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, inositol, galactitol), glycerol, and the like, including cyclitols (e.g., inositol); polyethylene glycol; an amino acid polymer; sulfur-containing reducing agents such as urea, glutathione, lipoic acid, sodium thioglycolate, thioglycerol, α -monothioglycerol, and sodium thiosulfate; low molecular weight polypeptides (e.g., peptides having 10 residues or fewer); hydrophilic polymers such as polyvinylpyrrolidone monosaccharides such as xylose, mannose, fructose, glucose; disaccharides, such as lactose, maltose, sucrose, and trehalose; and trisaccharides, such as raffinose; and polysaccharides such as dextran. The stabilizing agent may be present in an amount ranging from 0.5 wt% to 10 wt% per weight of antibody.
Nonionic surfactants or detergents (also referred to as "wetting agents") may be added to help solubilize glycoproteins and to protect glycoproteins from agitation-induced aggregation, which also permits exposure of the formulation to shear stress surfaces without causing denaturation of the proteins. Suitable nonionic surfactants include polysorbates (20, 80, etc.), poloxamers (184, 188, etc.), and pluronic polyols. The nonionic surfactant can be present in a range from about 0.05mg/mL to about 1.0 mg/mL.
A specific exemplary embodiment of an aqueous composition suitable for administration via intravenous infusion comprises 10mg/mL of the antibody, 15mM histidine buffer, pH 6.0, 8.0% (w/v) sucrose and 0.05% (w/v) polysorbate 80. The composition may be in the form of a lyophilized powder that upon reconstitution with 2.0mL of sterile water or other solution suitable for injection or infusion (e.g., 0.9% saline, Ringer's solution, lactated Ringer's solution, etc.), provides the above aqueous composition. The composition or compositions of other embodiments may also be in the form of a syringe or other device suitable for injection and/or infusion pre-filled with an amount of the composition suitable for a single administration of the antibody.
The antibodies of the invention may be administered alone (monotherapy) or in addition to other therapies, or with other drugs that may treat diseases caused by novel coronavirus infections. An amount of the antibody is administered, whether as monotherapy or in addition to or in conjunction with other therapies or drugs.
According to a further aspect of the invention there is provided a kit comprising an antibody or antigen-binding fragment thereof as hereinbefore described.
Further, the kit also comprises a color developing agent. The kit also contains instructions for diagnostic methods. The kit can utilize the inclusion of the aforementioned antibodies or antigen binding fragments thereof to detect the novel coronavirus in the biological sample.
Detection methods include conventional immunoassays including, without limitation, ELISA, RIA, FACS, immunohistochemistry, Westernblot, or immunoprecipitation, and the like. The antibodies or antigen-binding fragments thereof of the invention are useful for the detection of novel coronavirus S proteins.
The present invention provides a method for detecting a novel coronavirus S protein in a biological sample, comprising contacting the biological sample with an antibody or antigen-binding fragment thereof of the invention as described above, and detecting the binding of the antibody to the S protein to determine the presence or absence of the novel coronavirus in the sample. In one embodiment, the antibody is directly labeled with some detectable label. In another embodiment, the anti-S protein antibody (primary antibody) is unlabeled, while the secondary antibody or other molecule that can bind to the anti-S protein antibody is labeled. Those skilled in the art will recognize that the second antibody is selected to specifically bind to the species and class of the first antibody. For example, if the anti-S protein antibody is a human IgG, then the second antibody can be an anti-human IgG antibody. Other molecules capable of binding to antibodies include, without limitation, protein a and protein G.
Suitable antibody or second antibody labels are described above and include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, radioactive materials, and the like, suitable enzyme labels include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase, and the like, suitable prosthetic group complexes include streptavidin/biotin and ovalbumin/biotin, and the like, suitable fluorescent materials include umbelliferone, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, phycoerythrin, and the like, luminescent materials include luminol, and suitable radioactive materials include the like125I、131I、35S or3H, and the like.
In another embodiment, the novel coronavirus S protein in a biological sample can be detected by a competitive immunoassay, i.e., a test with a standard S protein labeled with a detectable substance and an unlabeled anti-S protein antibody. In this assay, the biological sample, labeled S protein standard and anti-S protein antibody are mixed together and the amount of labeled S protein standard bound to unlabeled antibody is determined. The amount of S protein in the biological sample is inversely proportional to the amount of labeled S protein standard bound by the anti-S protein antibody.
The invention also provides methods for producing the antibodies or antigen-binding fragments thereof of the invention, comprising production by immortalized cell lines, artificial synthesis, recombinant expression, or phage display techniques. In a particular embodiment, the method of the invention comprises the step of culturing the host cell as described above.
According to a further aspect of the invention, there is provided a use comprising any one of the following:
(1) use of the antibody or antigen-binding fragment thereof as described above for the preparation of a novel coronavirus detection product or diagnostic product;
(2) use of an antibody or antigen-binding fragment thereof as hereinbefore described in the manufacture of a medicament for the prophylaxis or treatment of a novel coronavirus infection;
(3) use of an antibody or antigen-binding fragment thereof as hereinbefore described in the manufacture of a medicament for the prophylaxis or treatment of a disease caused by a novel coronavirus infection;
(4) use of a composition as described hereinbefore for the preparation of a detection product or a diagnostic product for a novel coronavirus;
(5) use of a composition as hereinbefore described in the manufacture of a medicament for the prophylaxis or treatment of a novel coronavirus infection;
(6) use of a composition as hereinbefore described in the manufacture of a medicament for the prophylaxis or treatment of a disease caused by a novel coronavirus infection;
the test product or diagnostic product comprises the kit as described above.
The method for realizing the detection function or the diagnosis function by using the detection product or the diagnosis product of the present invention is as described above.
Definition and general techniques
Unless defined otherwise herein, scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Furthermore, as used herein, the singular includes the plural and plural referents unless the context requires otherwise. Generally, the relative terms of cell tissue culture, molecular biology, immunology, microbiology, genetics, protein and nucleic acid chemistry described herein are well known and commonly used in the art. The methods and techniques employed in the present invention are essentially performed according to conventional methods well known in the art, unless otherwise specified, and are described in various general or specific reference books, such as Sambrook et al molecular Cloning: ALaborory Manual, 2d ed., Cold Spring Harbor laboratory Press, Cold Spring Harbor, N.Y. (1989); ausubel et al, Current Protocols in Molecular Biology, Greene publishing associates (1992); harlow and Lane Antibodies: ALaboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990), and the like. Enzymatic reactions and purification techniques are performed according to manufacturer's instructions, and some are conventional in the art and some are described herein. The nomenclature used herein and the laboratory procedures in connection with analytical chemistry, organic synthetic chemistry, and pharmaceutical chemistry are those well known and commonly employed in the art. Chemical synthesis, chemical analysis, pharmaceutical preparation, prescription, transportation and treatment of patients all employ standard techniques.
Unless otherwise specified, the following terms are intended to have the following meanings:
the term "immunoglobulin" is a tetrameric molecule. Naturally occurring immunoglobulin tetramers are composed of two identical pairs of polypeptide chains, one "light" (about 25kD) and one "heavy" (about 50-70kD) chain per pair. The amino-terminal portion of each chain comprises a variable region of about 100-110 amino acids, primarily responsible for antigen recognition. The carboxy-terminal portion of each chain is the constant region primarily responsible for the functional effect. Human light chains are classified into two types, kappa chains and lambda chains; heavy chains are divided into five classes, μ, γ, α, and corresponding subclasses of antibodies, IgM, IgD, IgG, IgA, and IgE, respectively. The variable and constant regions of the light and heavy chains are each joined by a "J" region of about 12 amino acids, and the heavy chain also includes a "J" region of about 10 amino acids. The references are given in: see general, fundamental immunology ch.7(Paul, w., ed., 2nded. raven Press, n.y. (1989)). The variable region of each light/heavy chain pair forms the binding site for an antibody, and thus an intact immunoglobulin molecule has two binding sites.
Immunoglobulin chains have essentially the same structure: there are three regions of high variability between relatively conserved Framework Regions (FR), also called Complementarity Determining Regions (CDRs). The CDRs of both chains are aligned by the framework regions, enabling them to bind specific epitopes. The functional regions of either the light or heavy chain, from N-terminus to C-terminus, are FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4, in that order. The amino acid divisions contained in each functional region are consistent with the following references: kabat, Sequences of proteins of immunological Interest (National Institutes of Hlealth, Bethesda, Md. (1987and 1991)); chothia & Lesk, j.mol.biol.196: 901-917 (1987); chothia et al nature 342: 878-88(1989).
The term "antibody" refers to an intact immunoglobulin or an antigen-binding fragment thereof that competes with an intact antibody for a specific binding site. Antigen-binding fragments can be obtained from intact antibodies by recombinant protein techniques, enzymatic reactions or chemical cleavage. The antigen-binding fragment mainly comprises: fab, Fab ', F (ab') 2, Fv, dAb, Complementarity Determining Region (CDR) fragments, single chain antibodies (scFv), chimeric antibodies, diabodies, and polypeptides that include at least a portion of an immunoglobulin and have antigen binding properties. Fab is a monovalent fragment consisting of several domains, VL, VH, CL, CHI; f (ab') 2 is a bivalent fragment formed by two Fab fragments linked by a disulfide bond at the hinge region; fd fragment consists of VH and CHI composition; fv consists of VL and VH compositions of antibodies; dAb fragments (Wardet et al, Nature 341: 544-546, 1989) are composed of a VH domain. Single chain antibodies (scFv) are monovalent antibody molecules formed by joining VL and VH domains into a single protein chain via a synthetic linker (Bird et al, Science 242: 423-. Bivalent antibodies (diabodies) are bivalent, bispecific antibodies in which the VH and VL domains are in one polypeptide chain, but the linker between the two is too short to allow pairing of the two domains of the same chain, thus forcing pairing with the corresponding domain of the other chain to form two antigen binding sites (Holliger, P., et al., Proc. Natl. Acad. Sci. USA 90: 6444-. One or more CDRs may be inserted into a molecule in a covalent or non-covalent fashion to form an immunoadhesin. Immunoadhesins can be prepared by inserting a CDR into one large polypeptide chain, or by linking the CDR to another polypeptide chain in a covalent or non-covalent manner. The CDRs enable the immunoadhesin to specifically bind to a particular antigen of interest.
An antibody may have one or more than one binding site. If there is more than one binding site, they may be the same or different. For example, naturally occurring immunoglobulins have two identical binding sites, single chain antibodies or Fab fragments have only one binding site, whereas "bispecific" or "bifunctional" antibodies have two different binding sites. Bispecific antibodies can be obtained by a variety of methods, such as hybridoma cell fusion or binding of different Fab' fragments. The references are given in: songsivilai & Lachmann Clin/. exp.Immunol.79: 315- > 321 (19190); kostlny et al.j.immunol.148: 1547-1553(1992).
Antibodies or immunoglobulin molecule fragments or analogs can be prepared by techniques conventional in the art and as described herein. Preferably the amino-or carboxy-terminus of the fragment or analog is located in the vicinity of the functional domain. The structural and functional domains of antibodies can be determined by comparison with nucleotide and/or amino acid data in public or private databases. Preferred methods are computer-based comparisons to identify sequence motifs or to predict conformational domains that occur in other proteins of known structure and/or function. Methods have been available to determine whether protein sequences fold into known three-dimensional structures (Bowie et al science 253: 164 (1991)).
Preferred amino acid substitutions may be: (1) reduced susceptibility to proteolysis, (2) reduced susceptibility to oxidation, (3) altered binding affinity when protein complexes are formed, (4) altered binding affinity, and (5) other physicochemical or functional properties imparted or altered by these analogs. Analogs can contain a variety of mutations that differ from the sequence of the protein that occurs in nature. For example, single or multiple amino acid substitutions (particularly conservative amino acid substitutions) may be made in a naturally occurring protein sequence (particularly in portions other than the domains where intermolecular contacts occur). Conservative amino acid substitutions should not alter the structural properties of the parent sequence (e.g., the substituted amino acid should not disrupt the helical structure of the parent sequence, or alter other specific secondary structures of the parent sequence). Some examples of known secondary and quaternary Structures of Proteins are described in Proteins, Structures and Molecular Principles (Creighton, Ed., W.H.Freeman and Company, New York (1984)); introductionto Protein Structure (c.branden and j.tooze, eds., garland publishing, New York, n.y. (1991)); thornton et at. nature 354: 105(1991).
The twenty basic amino acids and their abbreviations used in this specification are in conventional format and are described in Immunology-A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, eds., Sinauuerasiates, Sunderland, Mass. (1991)). Stereoisomers of twenty basic amino acids (e.g., D-amino acids), unnatural amino acids such as α, α -disubstituted amino acids, N-alkyl amino acids, lactic acid, and other non-traditional amino acids can also be used in the polypeptides of the invention. Examples of non-traditional amino acids are: 4-hydroxyproline, gamma-carboxyglutamic acid, -N, N, N-trimethylserine, -N-acetyl lysine, O-phosphoserine, N-acetyl serine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). The polypeptide used herein is represented by an amino terminal on the left and a carboxy terminal on the right, consistent with conventional standard usage.
The term "polynucleotide" as used herein refers to a polymer of nucleotides of at least 10 bases in length, which may be ribonucleotides or deoxyribonucleotides, or modified forms of nucleotides. Polynucleotides include single-stranded or double-stranded forms of DNA.
The term "operably linked" sequence includes expression control sequences that are linked to the gene of interest, as well as expression control sequences that act in trans or are spaced apart from the gene of interest. "expression control sequence" as used herein refers to a polynucleotide sequence capable of effecting the expression or processing of a coding sequence to which it is linked. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; effective RNA processing signals such as splicing and PolyA signals; sequences capable of stabilizing cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., Kozak sequences); sequences that enhance protein stability; sequences that enhance protein secretion when desired. These control sequences vary from host to host in nature; in prokaryotes, these sequences typically include a promoter, a ribosome binding site, and a transcription termination sequence; in eukaryotes, these sequences generally include promoter and transcription termination sequences. The term "control sequences" includes at least all components necessary for expression and processing, as well as other components useful for expression and processing, such as leader sequences and fusion sequences.
The term "vector" as used herein refers to a nucleic acid molecule capable of transporting other nucleic acids to which it is linked. One type of vector is a "plasmid", which is a circular double-stranded DNA into which other DNA segments can be inserted. Another type of vector is a viral vector, into which additional DNA segments can be inserted into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they enter (e.g., bacterial vectors comprising a bacterial origin of replication and episomal mammalian vectors). Some vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon entry into the host cell, and are replicated along with the host genome. In addition, certain vectors can direct the expression of genes to which they are linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). Expression vectors used in recombinant DNA technology are generally in the form of plasmids. "plasmid" and "vector" are used interchangeably herein, as plasmids are the most commonly used form of vector. However, the invention encompasses other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve the same function.
The term "recombinant host cell" (or simply "host cell") as used herein refers to a cell which is transformed into a recombinant expression vector. It is noted that this term refers not only to the particular original cell, but also to its progeny. Certain alterations may occur in the progeny cell, either due to mutation or due to environmental factors, such that they are not identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.
The term "patient" includes human and animal patients.
Throughout the specification and claims the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated number or group of numbers but not the exclusion of any other number or group of numbers.
Drawings
FIG. 1 is a graph showing the results of detecting the specific binding of the antibody of the present invention to recombinant S-ECD using indirect ELISA;
FIG. 2 is a graph showing the results of detection of specific binding of the antibody of the present invention to recombinant S-RBD using indirect ELISA;
FIG. 3 shows an electrophoretogram of proteins for detecting binding of the antibody of the present invention to S-RBD and S-ECD using immunoprecipitation;
FIG. 4 is a graph showing the results of detecting the affinity of the antibody of the present invention to S-RBD and S-ECD using SPR assay, wherein A: FC 05; b: FC 08; c: FC 11;
FIG. 5 is a graph showing the results of measuring the neutralizing activity of the antibody of the present invention using an in vitro neutralization assay.
Detailed Description
The invention is further illustrated by the following examples. It should be understood that the examples of the present invention are for illustrative purposes and not intended to limit the present invention. Simple modifications of the invention in accordance with its spirit fall within the scope of the claimed invention.